Regular physical activity is considered key for the prevention of obesity and associated health conditions, but some people reap greater rewards from exercise than others. A new study may have shed light on why this is.
In a study of both mice and human subjects, researchers found that higher levels of selenoprotein P – a protein secreted by the liver – was associated with reduced exercise capacity and fewer exercise-related benefits.
Study co-author Hirofumi Misu, of the Kanazawa University Graduate School of Medical Sciences in Japan, and colleagues say that their findings indicate that selenoprotein P may be a driver of exercise resistance.
The researchers recently published their findings in the journal Nature Medicine.
According to current guidelines, adults should engage in around 150 minutes of moderate-intensity aerobic activity or 75 minutes of vigorous-intensity aerobic activity each week in order to maintain good health.
However, responsiveness to exercise – in terms of both endurance and metabolic health – can vary widely from person to person.
“In particular, some people show complete non-responsiveness to exercise training in terms of aerobic improvement. Similarly, 15-20 percent of patients with type 2 diabetes show a poor hypoglycemic effect to regular exercise therapy,” the authors note.
“These findings indicate that some people suffer from exercise resistance and derive limited benefits from the health-promoting effects of physical exercise.”
The precise mechanisms behind exercise resistance, however, have been unclear. Previous research has indicated that selenoprotein P might play a role, so Misu and colleagues set out to investigate this association further.
Firstly, the team assessed the effects of exercise training on two groups of mice: one that was deficient in selenoprotein P, and one group of wild-type mice (the controls).
Both groups ran on a treadmill for 30 minutes per day for 1 month. The researchers found that the selenoprotein P-deficient mice had double the exercise capacity of the wild-type mice.
Furthermore, at the end of the 1-month exercise training, the selenoprotein P-deficient mice demonstrated a larger reduction in blood glucose levels following an injection with the hormone insulin.
The researchers also administered selenoprotein P to wild-type mice prior to 1 month of exercise training.
These mice showed a reduction in phosphorylation of the enzyme AMPK in their muscles. The researchers explain that AMPK phosphorylation is associated with a number of exercise benefits.
Additionally, the researchers found that mice lacking LRP1 – a selenoprotein P receptor in muscles – were unable to absorb selenoprotein P into their muscles. Furthermore, AMPK phosphorylation was not impacted by exercise training.
Next, Misu and team sought to determine the effects of selenoprotein P on exercise in humans.
The researchers enrolled 31 women who were healthy but who did not engage in regular exercise.
All women took part in 8 weeks of aerobic training, and their maximal oxygen intake was monitored throughout as a measure of exercise endurance.
The team found that women who had high levels of selenoprotein P in their blood prior to the 8-week exercise program demonstrated a lower maximal oxygen intake than those with lower levels of selenoprotein P.
Taken together, the researchers believe that their results indicate that selenoprotein P contributes to exercise resistance by targeting the LRP1 receptor in muscles.
Further research is needed in order to gain a more detailed understating of how selenoprotein P impacts physical activity, but the team believes that this current study may pave the way for drugs that reduce selenoprotein P production to improve exercise endurance.
Misu and colleagues write:
“The current findings suggest that future screening for inhibitors of the [selenoprotein P]-LRP1 axis could identify exercise-enhancing drugs to treat physical-inactivity-associated diseases such as type 2 diabetes.”